Investigation Report on China Atorvastatin Market, 2009-2018

The report “Investigation Report on China Atorvastatin Market, 2009-2018″ by Research in China is now available at chinamarketresearchreports.com. Contact sales@chinamarketresearchreports.com with Investigation Report on China Atorvastatin Market, 2009-2018 in subject line and your contact details to purchase this report or get your questions answered.

The collection of ‘Life Sciences’ market research reports has a new addition of “Investigation Report on China Atorvastatin Market, 2009-2018”On chinamarketresearchreports.com. The prevalence rate of abnormal blood lipid in China is lower than that in most developed countries, but the average serum TC level of Chinese people is upgrading for the economic development and lifestyle change. Meanwhile, diabetes and metabolic syndromes are very common in China.

According to statistics, the prevalence rate of abnormal blood lipid is above 20% in the group aged at 18 or above. The total number of patients exceeds 200 million.

Inquire for discount @ http://www.chinamarketresearchreports.com/contacts/inquiry.php?name=114714 .

Blood lipidlowering drugs performs better than the overall drug market and cardiovascular system drugs. The expanding rate of blood lipidlowering drugs is obviously higher than that of cardiovascular system drugs and the proportion in the cardiovascular system drug market is increasing.
Atorvastatin, marketed by Pfizer as a calcium salt under the trade name Lipitor, is a member of the drug class known as statins, used for lowering blood cholesterol. It works by inhibiting HMGCoA reductase. In November 2011, Pfizer lost the patent protection in the USA. In May 2012, Pfizer lost the patent protection in the U.K. either. Liptor is the most popular drug of Pfizer with the accumulated sales value over USD 100 billion. It is the first drug with sales value breaking USD 100 billion in the history.

Complete report is available @ http://www.chinamarketresearchreports.com/114714.html . Read more on “Investigation Report on China Atorvastatin Market, 2009-2018” report below.

There are many enterprises producing APIs and finished products of atorvastatin. The market share of finished products is mainly occupied by Pfizer, which is above 80% by sales value every year. According to CRI's investigation, the CAGR of atorvastatin in China sample hospital market is above 40% during 20052013.
According to clinic research, atorvastatin has certain curative effects on osteoporosis, Alzheimer's disease, heart disease, organ transplantation, stroke and diabetes.

Through this report, the readers can acquire the following information:

·         Market Share of Major Atorvastatin Manufacturers in sample Hospitals in China

·         Sales price of atorvastatin in hospital market in China

·         Major atorvastatin enterprises in China

·         Market share of atorvastatin by dosage form in hospital market in China

·         Prospect of China atorvastatin market

The following enterprises and people are recommended to purchase this report:

·         Atorvastatin API and finished product manufacturers

·         Medical Institutions

·         Investors /research agencies focusing atorvastatin market

Table of Contents

1 Relevant Concepts of Atorvastatin
1.1 Indication
1.2 Sales Status on the Global Market
2 Market Overview of Atorvastatin in China
2.1 Patent Status
2.2 Major Manufacturers
2.3 Market Size
3 Investigation on Sales Value of Atorvastatin in China, 2009-2013
3.1 Total Sales Value
3.2 Sales Value by Region
4 Investigation on Market Share of Major Atorvastatin Manufacturers in China, 2009-2013
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 Investigation on Market Size of Atorvastatin by Dosage Form in China, 2009-2013
5.1 Market Share by Sales Value and Dosage Form
5.2 Market Share by Sales Volume and Dosage Form
6 Reference Price of Atorvastatin in Hospital Market in China, 2013
6.1 Price of Lipitor Produced by Dalian Pfizer Co., Ltd.
6.2 Price of Atorvastatin Produced by Ireland Pfizer Co., Ltd.
6.3 Price of Atorvastatin Produced by Henan Topfond Pharmaceutical Co., Ltd.
6.4 Price of Atorvastatin Produced by Beijing Jialin Pharmaceutical Co., Ltd.
6.5 Price of Atorvastatin Produced by Pfizer Co., Ltd. (the U.S.A.)
7 Analysis on Major Atorvastatin Manufacturers in China, 2009-2013
7.1 Pfizer
7.2 Beijing Jialin Pharmaceutical Co., Ltd.
7.3 Henan Topfond Pharmaceutical Co., Ltd.
7.4 Godecke (GE)
8 Prospect of China Atorvastatin Market, 2014-2018
8.1 Forecast on Market Size
8.2 Forecast on Competition Pattern

For further information on “Investigation Report on China Atorvastatin Market, 2009-2018” report OR for any other business research / market intelligence need on the ‘Life Sciences’ market (http://www.chinamarketresearchreports.com/cat/life-sciences.html .), contact sales@chinamarketresearchreports.com / Call +1 888 391 5441.